Fundraising Fox

Aligos Therapeutics

South San Francisco, US · Founded 2018 · 3 known investors

aligos.com ↗

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.

BiotechHealthtechin /aligos-therapeutics@AligosThera

Founders & leadership

HA
Hardean AchneckExecutive Officer
CN
Carole NeuchterleinDirector
PM
Peter MoldtDirector
SC
Sushmita ChandaExecutive Vice President - Preclinical Development
KG
Kathleen GlaubDirector
BD
Brian DowdExecutive Vice President - Controller
LQ
Lucinda QuanExecutive Vice President - General Counsel
LB
Leonid BeigelmanPresident
MY
Michael YiDirector
LM
Lawrence M. BlattChairman, President & CEO (Co-founder)
JS
Julian SymonsExecutive Vice President, Chief Scientific Officer
LA
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer & Chief Financial Officer

Investors · 3

Roche Venture FundBasel · $648K – $3.2M
MPM BioVentures 2014reportedCambridge
Vivo CapitalreportedPalo Alto · $10M – $50Mvia Jack Nielsen · board

Reported raises · per SEC filings

Form D private placements
▶$105MraisedFeb 2025 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bridget MartellDirector
  • Julian SymonsExecutive Officer
  • Margarita ChavezDirector
  • K. Peter HirthDirector
  • Heather PrestonDirector
  • Lesley Ann CalhounExecutive Officer
  • Lawrence M. BlattExecutive Officer, Director
  • James ScopaDirector
  • Hardean AchneckExecutive Officer
  • Carole NuechterleinDirector
Offering amount
$105M
Amount sold
$105M
Sales commissions
$2.7M
Placement agents
Piper Sandler & Co., Jefferies LLC
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$92.2MraisedNov 2023 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lesley Ann CalhounExecutive Officer
  • Bridget MartellDirector
  • Jack NielsenDirector
  • Leonid BeigelmanExecutive Officer, Director
  • Lucinda QuanExecutive Officer
  • Carole NuechterleinDirector
  • Julian SymonsExecutive Officer
  • Lawrence BlattExecutive Officer, Director
  • Matthew McClureExecutive Officer
  • James ScopaDirector
  • Peter HirthDirector
Offering amount
$92.2M
Amount sold
$92.2M
Sales commissions
$5.5M
Placement agents
PIPER SANDLER & CO.
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$85MraisedJan 2020 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter HirthDirector
  • Carole NeuchterleinDirector
  • Jack NielsenDirector
  • Peter MoldtDirector
  • Sushmita ChandaExecutive Officer
  • Julian SymonsExecutive Officer
  • Kathleen GlaubDirector
  • Brian DowdExecutive Officer
  • Lucinda QuanExecutive Officer
  • Leonid BeigelmanExecutive Officer, Director
  • Lawrence BlattExecutive Officer, Director
  • Michael YiDirector
  • Tom WoiwodeDirector
  • John FryExecutive Officer
Offering amount
$125M
Amount sold
$85M
First sale
Dec 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.